Efficacy and Safety of Immune Checkpoint Inhibitors for EGFR Mutated Non-Small Cell Lung Cancer
Author Information
Author(s): Zhu Lin, He Wenjuan, Xie Cunlei, Shu Yang, Zhang Chunxia, Zhu Yawen
Primary Institution: Wuhan Wuchang Hospital, Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China
Hypothesis
This study aimed to compare the efficacy and safety of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
Conclusion
The study suggests that ICI+antiangiogenesis+chemo may be beneficial for patients with EGFR-mutated NSCLC, but the differences were not statistically significant.
Supporting Evidence
- ICI+antiangiogenesis+chemo achieved the most favorable overall survival compared to other treatments.
- ICI monotherapy exhibited the lowest toxicity profile among the treatments studied.
- The study included a total of 11 eligible studies with 1462 patients.
Takeaway
This study looked at different treatments for lung cancer and found that combining certain therapies might help patients, but more research is needed to be sure.
Methodology
The study conducted a systematic review and network meta-analysis of 11 studies comparing various treatments for EGFR-mutated NSCLC.
Potential Biases
Some studies had moderate risk of bias due to concerns regarding blinding.
Limitations
The number of studies included was limited, and there was heterogeneity in treatment regimens.
Participant Demographics
The studies included patients with EGFR mutations, with varying demographics across different studies.
Statistical Information
Confidence Interval
95% CI 0.41–1.23
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website